Artemisinin resistance is rising in East Africa-leaving anti-malarials at risk of failure
A study published in The Lancet Infectious Diseases reveals that malaria parasites in East Africa are increasingly developing resistance to artemisinin, the primary drug used in standard treatments. Researchers warn that this trend threatens the effectiveness of global malaria control efforts.
Why it matters
Rising drug resistance in malaria parasites poses a significant public health risk, potentially rendering current first-line treatments ineffective across the continent.
edited by Lisa Lock , reviewed by Andrew Zinin
The article summarizes findings from a peer-reviewed medical study without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in